Cardiovascular Systems

Cardiovascular Systems is a medical device company. CSI is focused on developing and commercializing minimally invasive treatment solutions for vascular disease. Our primary focus is helping physicians conquer even the most difficult disease states, including calcium, given the complications it presents for the millions who suffer from peripheral arterial disease (PAD) and coronary artery disease (CAD). CSI is committed to clinical rigor, constant innovation, and a defining drive to set the standard in safe, effective, economical medical devices that improve patient outcomes.

Company Growth (employees)
Type
Public
HQ
Saint Paul, US
Size (employees)
581 (est)
Website
csi360.com
Cardiovascular Systems is headquartered in Saint Paul, US

Key People at Cardiovascular Systems

Scott R. Ward

Scott R. Ward

Chairman, President & CEO
Laurence L. Betterley

Laurence L. Betterley

CFO
Kevin J. Kenny

Kevin J. Kenny

Chief Operating Officer
James E. Flaherty

James E. Flaherty

CAO

Cardiovascular Systems Office Locations

Cardiovascular Systems has offices in Saint Paul and Rochester
Saint Paul, US (HQ)
1225 Old Hwy 8 Nw
Saint Paul, US
651 Campus Drive
Rochester, US
651 Campus Drive

Cardiovascular Systems Metrics

Cardiovascular Systems Financial Metrics

Cardiovascular Systems's revenue was reported to be $178.2 m in FY, 2016 which is a 2% decrease from the previous period.

Revenue (FY, 2016)

$178.2 m

Revenue growth (FY, 2015 - FY, 2016), %

(2%)

Gross profit (FY, 2016)

$142.8 m

Gross profit margin (FY, 2016), %

80%

Net income (FY, 2016)

($56 m)

EBIT (FY, 2016)

($56.1 m)

Market capitalization (23-May-2017)

$1 b

Closing share price (23-May-2017)

$31.6

Cash (30-Jun-2016)

$60.6 m
Cardiovascular Systems's current market capitalization is $1 b.
FY, 2014FY, 2015FY, 2016

Revenue

$136.6 m$181.5 m$178.2 m

Revenue growth, %

33%(2%)

Cost of goods sold

$31 m$39.5 m$35.4 m

Gross profit

$105.6 m$142 m$142.8 m

Gross profit Margin, %

77%78%80%

Operating expense total

$139.1 m$174.7 m$198.8 m

EBIT

($33.5 m)($32.6 m)($56.1 m)

EBIT margin, %

(25%)(18%)(31%)

Net Income

($35.3 m)($32.8 m)($56 m)
FY, 2014FY, 2015FY, 2016

Cash

$126.6 m$83.8 m$60.6 m

Accounts Receivable

$21.4 m$30.8 m$23.1 m

Inventories

$12.9 m$14 m$17.4 m

Current Assets

$162.7 m$133.9 m$104.9 m

PP&E

$15.3 m$32.9 m$32.5 m

Total Assets

$181.9 m$171.3 m$142.4 m

Accounts Payable

$12.7 m$9.8 m$8.5 m

Current Liabilities

$29.7 m$29.9 m$35.5 m

Non-Current Liabilities

$117 k

Total Liabilities

$29.8 m

Additional Paid-in Capital

$390.6 m$410.7 m$428.2 m

Retained Earnings

($238.6 m)($271.4 m)($327.4 m)

Total Equity

$139.4 m$100.9 m

Financial Leverage

1.2 x1.4 x
FY, 2014FY, 2015FY, 2016

Net Income

($35.3 m)($32.8 m)($56 m)

Depreciation and Amortization

$1.2 m$2.2 m$3.7 m

Accounts Receivable

($6.7 m)($11 m)$7.3 m

Inventories

($6.6 m)($1.1 m)($3.5 m)

Accounts Payable

$4.6 m$581 k($970 k)

Cash From Operating Activities

$58.7 m($42.8 m)($23.2 m)

Cash From Investing Activities

($13.4 m)($23 m)($3.8 m)

Cash From Financing Activities

$99 m$2.6 m$4.1 m

Interest Paid

$534 k$23 k
Y, 2016

Financial Leverage

1.4 x

Cardiovascular Systems Market Value History

Cardiovascular Systems Company Life

You may also be interested in